Roivant Sciences : View Presentation

Roivant

Overview

J.P. Morgan Healthcare Conference

January 9, 2023

Forward-Looking Statements

Forward-Looking Statements

This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned preclinical studies and clinical trials for our products and product candidates, including the information presented in this presentation with respect to RVT-3101 and the potential for RVT-3101 to improve the treatment of Ulcerative Colitis (UC) and Crohn's Disease (CD) and to be a first-in-class agent, any commercial potential of our product candidates and the receipt of proceeds from the expected sale of the Myovant top-up shares to Sumitomo Pharma, are forward-looking statements.

These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements. The interim data presented here for RVT-3101 is from the induction period of the TUSCANY-2 study and is based on an interim analysis of key efficacy and safety data, and such data may change following completion of the clinical trial and may not accurately reflect the complete results of the TUSCANY-2 study.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the

forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the sections captioned "Risk Factors" and "Forward-Looking Statements" of our filings with the U.S. Securities and Exchange Commission, available at www.sec.gov and investor.roivant.com. We operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation includes data, results and attributes for RVT-3101 and certain other products and product candidates generated from separate, independent studies and that do not come from head-to-head analysis. Differences exist between study or trial designs and subject characteristics and caution should be exercised when comparing data across studies. Data regarding other products and product candidates is based on publicly available information.

Disclaimer

Today's discussions and presentation are intended for the investor community only; they are not intended to promote the product candidates referenced herein or otherwise influence healthcare prescribing decisions.

2

For investor audiences only

2022 Has Been an Incredible Year for Roivant …

Commercial Launch of VTAMA

Became #1 most prescribed branded topical for psoriasis 8 weeks into launch

Executed first major PBM/payer contract

Japanese partner reported positive

topline results in Phase 3 trial in

AD

Demonstrated favorable PK and safety in pediatric subjects with

AD

Pipeline Composition

RVT-3101 and brepocitinib: Announced collaborations with

Pfizer

IMVT-1402: Unveiled next-

generation anti-FcRn

Batoclimab: Announced new indications

Optimized pipeline and extended runway by discontinuing six programs

Clinical Progress

Brepocitinib: Initiated Phase 3 trial in DM

Brepocitinib: Completed enrollment in global Phase 2B trial in SLE

Namilumab: Initiated Phase 2 trial

in sarcoidosis

RVT-2001: Expanded ongoing

Phase 1/2 trial in lower-risk MDS

Batoclimab: Initiated Phase 3 trials

in MG and TED

Additional Upside

Established multiple partnerships in targeted protein degradation with aggregate milestone payments over $1B plus product royalties

LNP patent litigation progressed in Roivant's favor

3

For investor audiences only

• In Which We Built an Industry-Leading 2023 Catalyst Calendar

	JPM 2022
Program	Catalyst	Expected Timing
VTAMA	Topline data from Phase 3
(tapinarof)	1H 2023
trials in atopic dermatitis
cream

		JPM 2023
	Program	Catalyst	Expected Timing
	RVT-3101	Induction data from Phase	1Q 2023
	2B trial in ulcerative colitis
	VTAMA
	Topline data from Phase 3
	(tapinarof)	1H 2023
	trials in atopic dermatitis
	cream
		Final data including chronic
	RVT-3101	therapy period from Phase	1H 2023
		2B trial in ulcerative colitis
	IMVT-1402	Initial data from Phase 1	Mid 2023
	trial
		Topline data from
	Brepocitinib	potentially registrational	2H 2023
	Phase 2B trial in systemic

lupus erythematosus

4

For investor audiences only

Roivant Pipeline

	Modality	Preclinical	Phase 1	Phase 2	Phase 3	Approved
Psoriasis | Dermavant	Topical					►
Atopic Dermatitis | Dermavant	Topical				►
RVT-3101 Ulcerative Colitis | New Vant	Biologic			►
RVT-3101 Crohn's Diseases | New Vant	Biologic			►
BREPOCITINIB Dermatomyositis | Priovant	Small Molecule				►
BREPOCITINIB Systemic Lupus Erythematosus | Priovant	Small Molecule			►
BREPOCITINIB Other Indications | Priovant	Small Molecule			►
BATOCLIMAB Myasthenia Gravis | Immunovant	Biologic				►
BATOCLIMAB Thyroid Eye Disease | Immunovant	Biologic				►
BATOCLIMAB Chronic Inflammatory Demyelinating Polyneuropathy | Immunovant	Biologic			►
BATOCLIMAB Graves' Disease | Immunovant	Biologic			►
BATOCLIMAB Warm Autoimmune Hemolytic Anemia | Immunovant	Biologic			►
IMVT-1402 Numerous Indications | Immunovant	Biologic		►
NAMILUMAB Sarcoidosis | Kinevant	Biologic			►
RVT-2001 Transfusion-Dependent Anemia in Patients with Lower-Risk MDS | Hemavant	Small Molecule		►

Pipeline reflects both ongoing clinical trials and expected upcoming trials. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis.

• Represents registrational or potentially registrational trials

5

For investor audiences only